Project Grant R01NS145295
Award Date 8/1/25
Completion Date 5/31/30
Dollars Obligated $614K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Worcester, MA 01655, USA
Similar Awards
- This federal Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847) provides $343,635 to Syntis Bio Inc. to advance the development of SYNT-213, a potentially transformative once-daily oral therapy for the treatment of Maple Syrup Urine Disease (MSUD). The project aims to optimize SYNT-213, which combines Syntis Bio's Gastrointestinal Synthetic Epithelial Lining (GSEL) technology with a protease-stable leucine decarboxylase enzyme...
- This $147,486 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) supports research to understand the disease mechanism and develop gene therapy for a common and understudied STXBP1 missense variant that causes severe developmental and epileptic encephalopathy. The applicant has established a mouse model that recapitulates key neurological symptoms of this...
- This federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) supports research to develop a novel gene therapy approach to reduce neurotoxicity in Parkinson's disease. The $1,009,212 award to the Van Andel Research Institute in Grand Rapids, MI will fund pharmacodynamic, pharmacokinetic, and in vivo efficacy studies to enhance the activity of the...
- This federal Project Grant award of $169,000 from the National Institute of Neurological Disorders and Stroke (NINDS, CFDA 93.853) will support the development of a comprehensive, open-source, and user-friendly online platform for neurometabolic diseases. The platform will include clinical, biochemical, radiological, and therapeutic data on over 1,600 known neurometabolic diseases. This initiative aims to enhance understanding, clinical management, and research insights into these rare genetic...
- This $453,033 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) will fund research by Case Western Reserve University to investigate the role of microglia-mediated glycosaminoglycan catabolism in the neuropathology of Mucopolysaccharidosis VII (MPS VII). The key objectives are to develop new genetic tools to conditionally ablate beta-glucuronidase...
- This Project Grant award of $460,625 from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, is supporting research to investigate the roles of the deubiquitylation pathway in TDP-43 pathology associated with amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). The research is being conducted by the University of Massachusetts Medical School (UMMS) and...
- This $699,818 Project Grant awarded on July 8, 2025 by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) aims to develop an effective adeno-associated virus (AAV) gene therapy product for treating Mucopolysaccharidosis Type IIIC (MPS IIIC), a rare and devastating lysosomal storage disease. The project seeks to leverage extracellular vesicle-mediated mRNA trafficking to...
- This $226,500 federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, will support a 2-year research project to characterize and treat peripheral nervous system dysfunction in Sanfilippo syndrome (mucopolysaccharidosis type IIIA). The award will enable researchers at the University of Georgia Research Foundation to develop novel disease...
- This $233,250 Project Grant awarded by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) supports the development and evaluation of a highly sensitive luciferase-based biosensor to quantify endogenous UBE3A ubiquitin ligase activity in cells and the brain. The University of North Carolina at Chapel Hill will conduct this research from March 2025 through February 2027, with the...
- This federal Project Grant award, funded by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, aims to develop a non-viral gene-editing therapy using lipid nanoparticle (LNP)/mRNA complexes to correct UBE3A gene overexpression in neural stem progenitor cells during fetal brain development. The $654,339 award to the University of California, Davis will support research to...